Misplaced Pages

Utthara Nayar

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Cancer researcher
The topic of this article may not meet Misplaced Pages's notability guideline for academics. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted.
Find sources: "Utthara Nayar" – news · newspapers · books · scholar · JSTOR (October 2018) (Learn how and when to remove this message)

Utthara Nayar is a cancer researcher based in Boston, Massachusetts. Her work focuses specifically on breast cancer.

Biography

Nayar lived in the country of Oman during her childhood. She was encouraged to participate in science, with her passion being in biology and physics.

For her undergraduate degree Nayar attended the University of Wisconsin-Madison as a part of their biology Honors Program with a major in biology. She earned her doctorate through Weill Cornell Medical College. She is employed at Dana-Farber Cancer Institute as a researcher in the lab of Nikhil Wagle. She is also a member of a team at Harvard Medical School as a research affiliate.

Research

At the Dana-Farber Cancer Institute, Nayar and her team have been investigating metastatic breast cancer and how hormones affect patient treatment. For some forms of breast cancer a patient is ER positive, or estrogen receptor positive, meaning that tumors grow as the levels of estrogen in the body increase. For this type of breast cancer, patients quickly become resistant to the treatment methods available and their bodies stop responding to any medical help they receive, seemingly without any connection. However, Nayar and her team found a link in patients who became resistant to ER positive treatment- many had HER-2 gene mutations. This possible discovery has spurred on a five-year phase 2 trial by Nayar and her team, investigating the connection between ER positive treatment rejection and the HER-2 gene.

Publications

Journal Publications
Year Publication
2013 Nayar, U., Pin Lu, Goldstein, R. L., Vider, J., Ballon, G., Rodina, A., ... Cesarman, E. (2013). Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood, 122(16), 2837–2847. https://doi.org/10.1182/blood-2013-01-479972
2017 Nayar, U., Sadek, J., Reichel, J., Hernandez-Hopkins, D., Akar, G., Barelli, P. J., ... Cesarman, E. (2017). Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies. Journal of Clinical Investigation, 127(6), 2066–2080. https://doi.org/10.1172/JCI83936

Awards and recognition

In 2012 while at Cornell, Nayar was awarded the AACR-Aflac, Inc. Scholar-in-Training Award.

In 2018 while working at the Dana-Farber Cancer Institute, Nayar was awarded the 2018 Women In Cancer Research Scholar Award by the American Association for Cancer Research for her work with breast cancer.

References

  1. ^ "Awards and Honors Across Weill Cornell Medical College". WCM Newsroom. Retrieved 2018-10-03.
  2. ^ "Utthara Nayar is targeting cancer drug resistance". Broad Institute. 2018-03-19. Retrieved 2018-10-03.
  3. ^ "Why Some Breast Cancer Becomes Resistant to Hormone Therapy". www.medscape.com. Retrieved 2018-10-03.
  4. ^ "HER-2 mutations linked to hormone therapy resistance in breast cancer subtype". Retrieved 2018-10-03.
  5. "Fulvestrant plus neratinib reversed treatment-acquired HER2 mutations in metastatic ER+ breast cancer". pm360online.com. 21 November 2014. Retrieved 2018-10-04.
  6. Nayar, Utthara; Lu, Pin; Goldstein, Rebecca L.; Vider, Jelena; Ballon, Gianna; Rodina, Anna; Taldone, Tony; Erdjument-Bromage, Hediye; Chomet, Max (2013-10-17). "Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies". Blood. 122 (16): 2837–2847. doi:10.1182/blood-2013-01-479972. ISSN 0006-4971. PMC 3798998. PMID 23943653.
  7. Nayar, Utthara; Sadek, Jouliana; Reichel, Jonathan; Hernandez-Hopkins, Denise; Akar, Gunkut; Barelli, Peter J.; Sahai, Michelle A.; Zhou, Hufeng; Totonchy, Jennifer (2017-05-15). "Identification of a nucleoside analog active against adenosine kinase–expressing plasma cell malignancies". Journal of Clinical Investigation. 127 (6): 2066–2080. doi:10.1172/jci83936. ISSN 0021-9738. PMC 5451239. PMID 28504647.
  8. "2018 Women in Cancer Research Scholar Awards". www.aacr.org. Retrieved 2018-10-03.
Categories: